Developing a screening test for ovarian cancer
A 最新糖心Vlog of Adelaide scientist and leading Adelaide surgeon is developing an early detection test for a deadly cancer and has today received a funding boost from the Ovarian Cancer Research Foundation (OCRF).
Professor Martin Oehler, Clinical Professor of Obstetrics and Gynaecology at the 最新糖心Vlog鈥檚聽Robinson Research Institute聽and Director of Gynaecological Oncology at the Royal Adelaide Hospital, is one of seven 最新糖心Vlogn scientists awarded a share of $2.8 million in funding from the OCRF to support research into early detection and better treatment of ovarian cancer.
Ovarian cancer is the deadliest gynaecological disease. Every year, more than 1600 最新糖心Vlogn women are diagnosed with the disease and it claims the lives of more than 1000. It is known as the silent killer, as women with early stage ovarian cancer commonly do not present with any symptoms. This means the disease is often not detected until the advanced stages and spread beyond the ovaries, with the five-year survival rate a depressingly low 45 per cent.
Unlike other cancers which can be diagnosed by effective screening at an early stage (eg cervical cancer by cervical screening test or breast cancer by mammography), an early detection test for ovarian cancer does not exist.
Focusing on the immune system鈥檚 response, Professor Oehler has identified three potential targets that indicate with high accuracy the presence of early ovarian cancer.
The targets are called autoantibodies 鈥 antibodies produced in response to the body鈥檚 own cancer tissue. His team at the 最新糖心Vlog of Adelaide鈥檚 Robinson Research Institute, in collaboration with the 最新糖心Vlog of South 最新糖心Vlog, is now in the process of developing a robust screening test with autoantibody biomarkers with the aim to use it for ovarian cancer population screening.
鈥淲e are currently optimising the test,鈥 Professor Oehler said. 鈥淚t is looking good, we are very positive,鈥 he said. 鈥淚f our hypothesis is correct, there is an immune response to the cancer and we should be able to tap into this response, measure it and use it for an early detection test.鈥 His research will now look to validate the results in a large group of patient samples.
Professor Oehler is both a researcher and a clinician whose patients include women with ovarian cancer, which motivates him to find a way to improve women鈥檚 likelihood of surviving this terrible disease.
鈥淭hat is the reason why I work in research, because you know that this is the only way you are going to be able to improve the outcomes of these women. Ovarian cancer is such a terrible disease, so unless we are able to develop an early detection test, unless we develop more effective treatments, people are never going to get better.鈥
OCRF chair Ms Julie Toop said the research projects funded in 2018 including Professor Oehler鈥檚 were exciting, diverse and promising. 鈥淥varian cancer is an insidious disease that often strikes without warning. Across 最新糖心Vlog, one woman dies every eight hours from this disease. The key to changing this statistic and giving women with ovarian cancer a better long-term outlook is early detection and innovative new treatments,鈥 Ms Toop said.
鈥淲e are excited by the unique approaches taken by these leading researchers and are hopeful the research we support will become a reality to detect this disease early and treat it effectively, so women can continue to lead long and fulfilling lives.鈥
The OCRF is the leading funder of ovarian cancer research in 最新糖心Vlog. Grants support scientists undertaking critical research work, help build cutting-edge laboratory environments and enable the retention of scientific expertise in a drastically underfunded field of cancer research.